Irina Rivkind Koffler
Stock Analyst
(n/a)
# 4,651
Out of 4,653 analysts
31
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Irina Rivkind Koffler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Assumes: Buy | $30 | $11.88 | +152.53% | 4 | Sep 5, 2019 | |
| DERM Journey Medical | Upgrades: Buy | $17 → $14 | $5.08 | +175.59% | 4 | Jun 6, 2019 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Neutral | $146 → $148 | $124.27 | +19.10% | 6 | May 8, 2019 | |
| PCRX Pacira BioSciences | Upgrades: Neutral | $29 → $38 | $16.37 | +132.13% | 4 | May 6, 2019 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $61 → $63 | $36.18 | +74.13% | 2 | Dec 17, 2018 | |
| TEVA Teva Pharmaceutical | Maintains: Buy | $28 → $29 | $16.75 | +73.13% | 7 | Sep 17, 2018 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Buy | n/a | $4.11 | - | 4 | May 2, 2018 |
Evolus
Sep 5, 2019
Assumes: Buy
Price Target: $30
Current: $11.88
Upside: +152.53%
Journey Medical
Jun 6, 2019
Upgrades: Buy
Price Target: $17 → $14
Current: $5.08
Upside: +175.59%
Jazz Pharmaceuticals
May 8, 2019
Maintains: Neutral
Price Target: $146 → $148
Current: $124.27
Upside: +19.10%
Pacira BioSciences
May 6, 2019
Upgrades: Neutral
Price Target: $29 → $38
Current: $16.37
Upside: +132.13%
Supernus Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $61 → $63
Current: $36.18
Upside: +74.13%
Teva Pharmaceutical
Sep 17, 2018
Maintains: Buy
Price Target: $28 → $29
Current: $16.75
Upside: +73.13%
Ironwood Pharmaceuticals
May 2, 2018
Upgrades: Buy
Price Target: n/a
Current: $4.11
Upside: -